# Atossa Therapeutics, Inc.: overview ATOS · Nasdaq · CIK 1488039 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/atos.md) · [Financials](/companies/atos/financials.md) · [Filings](/companies/atos/filings.md) · [Insiders](/companies/atos/insiders.md) Latest reported revenue: [$0](/filings/0001144204-16-134190.md) for Q3 FY2016, three months to 2016-09-30, from the 10-Q filed Nov 14, 2016 (XBRL us-gaap:SalesRevenueNet, accession 0001144204-16-134190). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.06)](/filings/0001193125-25-276160.md) | not reported | [(0.78)](/filings/0001193125-26-213423.md) | [(0.98)](/filings/0001193125-26-339257.md) | [(0.07)](/filings/0001193125-25-276160.md) | not reported | [(1.11)](/filings/0001193125-26-213423.md) | [(0.95)](/filings/0001193125-26-339257.md) | | Free cash flow | $m | [(4.8) d](/filings/0001193125-25-276160.md) | [(7.1) d](/filings/0001193125-26-124396.md) | [(6.0)](/filings/0001193125-26-213423.md) | [(7.3) d](/filings/0001193125-26-339257.md) | [(6.0) d](/filings/0001193125-25-276160.md) | [(10.5) d](/filings/0001193125-26-124396.md) | [(9.6)](/filings/0001193125-26-213423.md) | [(9.6) d](/filings/0001193125-26-339257.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.18)](/filings/0001437749-22-004614.md) | [(0.21)](/filings/0000950170-24-039306.md) | [(0.24)](/filings/0000950170-25-044099.md) | [(3.04)](/filings/0001193125-26-124396.md) | [(4.04)](/filings/0001193125-26-124396.md) | | Free cash flow | $m | [(16.5)](/filings/0001437749-23-007531.md) | [(20.8)](/filings/0000950170-24-039306.md) | [(21.0)](/filings/0000950170-25-044099.md) | [(21.0)](/filings/0001193125-26-124396.md) | [(29.8)](/filings/0001193125-26-124396.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atos/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $698.2k | 361,747 | | Added +12,651 | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $498.4k | 258,234 | | Added +3,100 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $317.2k | 164,358 | | Added +31,189 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $254.8k | 132,043 | | Added +23,036 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $178.3k | 92,382 | | Reduced −4,679 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $159.5k | 82,620 | | Reduced −9,414 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $109.2k | 56,602 | | New +56,602 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $101.5k | 52,583 | | Added +348 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $89.8k | 46,508 | | Reduced −20,231 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $76.7k | 39,761 | | Unchanged | ## Recent filings [All 638 filings](/companies/atos/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-09 | 12:15 ET | [8-K](/filings/0001193125-26-418560.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-418560 | | 2026-09-29 | 12:00 ET | [8-K](/filings/0001193125-26-406036.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-406036 | | 2026-09-18 | 21:00 ET | [8-K](/filings/0001193125-26-395694.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-395694 | | 2026-08-07 | 12:45 ET | [8-K](/filings/0001193125-26-339292.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-339292 | | 2026-08-07 | 12:30 ET | [10-Q](/filings/0001193125-26-339257.md) | Quarterly report, period 2026-06-30 | 0001193125-26-339257 | | 2026-06-11 | 12:00 ET | [8-K](/filings/0001193125-26-266717.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-266717 | | 2026-05-08 | 12:45 ET | [8-K](/filings/0001193125-26-213439.md) | 9.01 Financial statements and exhibits | 0001193125-26-213439 | | 2026-05-08 | 12:30 ET | [10-Q](/filings/0001193125-26-213423.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213423 | | 2026-05-08 | 12:00 ET | [8-K](/filings/0001193125-26-213373.md) | 5.07 Shareholder vote results | 0001193125-26-213373 | | 2026-04-16 | 12:30 ET | [8-K](/filings/0001193125-26-158030.md) | 8.01 Other events | 0001193125-26-158030 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-124396.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1488039 - Tickers: ATOS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.